8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

     Date of report (Date of earliest event reported):  January 24, 2007

                           Integrated BioPharma, Inc.
             (Exact Name of Registrant as Specified in Its Charter)

                                    Delaware
                 (State or Other Jurisdiction of Incorporation)

       000-28876                                          22-2407475
(Commission File Number)                       (IRS Employer Identification No.)

           225 Long Avenue
        Hillside, New Jersey                               07205
(Address of Principal Executive Offices)                 (Zip Code)

                                 (973) 926-0816
              (Registrant's Telephone Number, Including Area Code)



          (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))




Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.

         On January 24, 2007, Integrated BioPharma, Inc. (the "Company")
notified The American Stock Exchange ("AMEX") of its intention to transfer the
listing of its common stock from AMEX to the Nasdaq Global Market ("NASDAQ").
The Company expects that trading will commence on NASDAQ on February 5, 2007 and
that the stock trading symbol will be "INBP." A copy of the Company's press
release announcing the Company's intention to transfer the listing of the
Company's common stock to NASDAQ is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.      Description

99.1             Press Release of Integrated BioPharma, Inc., dated
                 January 24, 2007.





                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                            INTEGRATED BIOPHARMA, INC.


Date:  January 24, 2007                     By:/s/ Dina Masi
                                            ----------------
                                            Dina Masi
                                            Chief Financial Officer

EX-99

                                                                    EXHIBIT 99.1


   INTEGRATED BIOPHARMA TO LIST ITS COMMON SHARES ON THE NASDAQ GLOBAL MARKET

HILLSIDE, NEW JERSEY (January 24, 2007) - Integrated BioPharma, Inc. (AMEX:INB)
announced today that it has received approval from the NASDAQ Stock Market, Inc.
to list its common shares on the NASDAQ Global Market under the symbol "INBP."
The Company's common shares will begin trading on NASDAQ upon the completion of
certain final regulatory requirements, which the Company currently expects will
occur on February 5, 2007, at which time the common shares will be de-listed
from the American Stock Exchange. Until that time, the Company's common shares
will continue to trade on the American Stock Exchange under the symbol "INB".

E. Gerald Kay, Chief Executive Officer, stated that the Company believes that
transferring its listing to NASDAQ will provide the Company with enhanced access
to the broader capital markets, superior liquidity and better execution quality.

About Integrated BioPharma Inc (INB)

Integrated BioPharma is a unique grouping of companies presently serving the
varied needs of the health care industry. Through its nutraceutical business,
the Company creates, develops, manufactures and markets products worldwide. The
Company's biotechnology business uses its patented plant-based technology to
produce vaccines and therapeutic antibodies. Its pharmaceutical business
operates a cGMP facility for the production and sale of Paclitaxel and related
drugs and provides technical services through its contract research
organization. Further information is available at www.iBioPharma.com.

Statements included in this release related to Integrated BioPharma, Inc. may
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve a number of
risks and uncertainties such as competitive factors, technological development,
market demand, and the company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. Further information on
potential risk factors that could affect the company's financial results can be
found in the company's Reports filed with the Securities and Exchange
Commission.